- Home
- RIGL vs AVNS Comparison
RIGL vs AVNS Comparison
Compare RIGL & AVNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | AVNS |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 521.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | AVNS |
|---|---|---|
| Price | $37.67 | $12.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.20 | N/A |
| AVG Volume (30 Days) | ★ 585.3K | 563.1K |
| Earning Date | 03-03-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | $282,076,000.00 | ★ $699,900,000.00 |
| Revenue This Year | $65.53 | $3.07 |
| Revenue Next Year | $0.22 | $2.16 |
| P/E Ratio | $6.05 | ★ N/A |
| Revenue Growth | ★ 79.13 | 2.70 |
| 52 Week Low | $15.50 | $9.30 |
| 52 Week High | $52.24 | $17.69 |
Technical Indicators
Market Signals| Indicator | RIGL | AVNS |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 59.92 |
| Support Level | $37.00 | $11.38 |
| Resistance Level | $39.49 | $12.41 |
| Average True Range (ATR) | 2.62 | 0.43 |
| MACD | -0.73 | 0.07 |
| Stochastic Oscillator | 4.46 | 93.33 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.